Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Academic Article uri icon

Overview

authors

  • Zeidan, Amer M
  • Fenaux, Pierre
  • Gobbi, Marco
  • Mayer, Jiří
  • Roboz, Gail J
  • Krauter, Jürgen
  • Robak, Tadeusz
  • Kantarjian, Hagop M
  • Novák, Jan
  • Jedrzejczak, Wieslaw W
  • Thomas, Xavier
  • Ojeda-Uribe, Mario
  • Miyazaki, Yasushi
  • Min, Yoo Hong
  • Yeh, Su-Peng
  • Brandwein, Joseph M
  • Gercheva, Liana
  • Demeter, Judit
  • Griffiths, Elizabeth A
  • Yee, Karen W L
  • Issa, Jean-Pierre J
  • Bewersdorf, Jan Philipp
  • Keer, Harold
  • Hao, Yong
  • Azab, Mohammad
  • Döhner, Hartmut

publication date

  • July 21, 2022

Research

keywords

  • Azacitidine
  • Leukemia, Myeloid, Acute

Identity

PubMed Central ID

  • PMC9305088

Scopus Document Identifier

  • 85134777585

Digital Object Identifier (DOI)

  • 10.1182/blood.2022015832

PubMed ID

  • 35507690

Additional Document Info

volume

  • 140

issue

  • 3